Hepatocellular Carcinoma Clinical Trials

60 studies are recruiting for hepatocellular carcinoma in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers

   This is a prospective pilot protocol investigating whether ctDNA detection be improved by sampling the cancer draining vein versus the standard practice of sampling from a peripheral vein in patients who are undergoing biopsies for hepatobiliary and pancreatic cancers.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California

   Run by

   University of California, Irvine

   See if you can join NCT05497531 on ClinicalTrials.gov

2. HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer

   This is a pilot and feasibility study assessing the role of quantitative multiparametric MRI and blood-based biomarkers for the measurement of liver function in patients receiving radiation therapy for liver cancer, including hepatocellular carcinoma (HCC), cholangiocarcinoma, or liver metastases r…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Montefiore Medical Center, The Bronx, New York

   Run by

   Montefiore Medical Center

   See if you can join NCT06899152 on ClinicalTrials.gov

3. Molecular Basis of Pediatric Liver Cancer

   The purpose of this retrospective and prospective project is to understand the molecular and genetic basis of liver cancer of childhood. Understanding the molecular and genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.

   Stage

   Not phased

   Ages

   0 to 99

   Site

   UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania

   Run by

   University of Pittsburgh

   See if you can join NCT03959800 on ClinicalTrials.gov

4. IDOV-Immune for Advanced Solid Tumors

   This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments. Oncolytic viruses are designed to infect and destroy cancer cells and have the potent…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Washington University School of Medicine, St Louis, Missouri

   Locations

   5 in total

   Run by

   ViroMissile, Inc.

   See if you can join NCT06910657 on ClinicalTrials.gov

5. Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant

   A single institution, single arm, two-cohort feasibility trial to evaluate the combination of locoregional Y\^90 therapy with systemic atezolizumab and bevacizumab, in participants presenting with hepatocellular carcinoma (HCC) 1) within Milan Criteria (MC) with AFP ≥ 400 ng/ml as a means of bridge…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT07059494 on ClinicalTrials.gov

6. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

   This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tum…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   62 in total

   Run by

   Seagen, a wholly owned subsidiary of Pfizer

   See if you can join NCT05208762 on ClinicalTrials.gov

7. AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma

   This study will test the hypothesis that a novel combination of three drugs (sorafenib, sonidegib, and irinotecan), in conjunction with individually optimized doses, can be safely administered and lead to improved clinical outcomes in patients with hepatocellular carcinoma compared to standard of c…

   Stage

   Phase 2

   Ages

   18 to 99

   Site

   University of Florida, Gainesville, Florida

   Run by

   University of Florida

   See if you can join NCT05669339 on ClinicalTrials.gov

8. Multi-analyte Blood Test Clinical Trial

   The objective of this study is the acquisition of whole blood samples and serum samples from participants with untreated Hepatocellular Carcinoma (HCC) and subjects undergoing Hepatocellular Carcinoma (HCC) surveillance. These samples will be used for research purposes to develop and validate the H…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Gastroenterology and Liver Institute, Escondido, California

   Locations

   7 in total

   Run by

   Helio Genomics

   See if you can join NCT05199259 on ClinicalTrials.gov

9. An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

   It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma. The researchers will develop and validate a liquid biopsy, based on exosomal content analysis and powered by machine learning, to help clinicians differentiate the…

   Stage

   Not phased

   Ages

   18 and older

   Site

   City of Hope Medical Center, Duarte, California

   Locations

   5 in total

   Run by

   City of Hope Medical Center

   See if you can join NCT06342414 on ClinicalTrials.gov

10. CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules

    The study will be conducted at the following locations: 1. UT Southwestern Medical Center 2. Parkland Health and Hospital System 3. University of Michigan Investigators will prospectively compare the performance of dynamic contrast enhanced abbreviated MRI (AMRI) and contrast-enhanced ultrasound fo…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Michigan, Ann Arbor, Michigan

    Locations

    2 in total

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT06184152 on ClinicalTrials.gov

11. Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

    Patients with histologically or cytologically confirmed advanced melanoma, renal cell carcinoma, NSCLC, HCC (Child Pugh Class A only), MSI-High solid tumors, Urothelial Cancer, GE junction/Gastric Adenocarcinoma, or HNSCC for which current standard of care treatment for their stage of disease would…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

    Run by

    Dan Zandberg

    See if you can join NCT04114136 on ClinicalTrials.gov

12. A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma

    To evaluate the relationship between 18F-FSPG uptake in HCC lesions, ctDNA in blood and clinical response to Y90 radioembolization therapy in patients with hepatocellular carcinoma (HCC) by SOC imaging.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas M. D. Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT07116486 on ClinicalTrials.gov

13. Y-90 Treatment Response Using Transarterial Radioembolization

    This prospective clinical study will examine the ability of contrast-enhanced ultrasound (CEUS) to assess the treatment response of hepatocellular carcinoma (HCC) to transarterial radioembolization (TARE). HCC is the third leading cause of cancer mortality worldwide and the single fastest growing c…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania

    Run by

    Thomas Jefferson University

    See if you can join NCT07145801 on ClinicalTrials.gov

14. Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

    The purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment in adult patients with advanced hepatocellular carcinoma. The immunotherapy consists of a standard…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Northwestern University, Chicago, Illinois

    Locations

    7 in total

    Run by

    Northwestern University

    See if you can join NCT05620771 on ClinicalTrials.gov

15. Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

    This is a phase I/II study to evaluate the safety of combining intravenous (IV) atezolizumab and bevacizumab every three weeks, with daily oral cyclophosphamide and pharmacokinetic (PK)-guided sorafenib in children and adolescent and young adults (AYA) with relapsed or refractory solid malignancies…

    Stage

    Phase 1

    Ages

    Up to 30

    Site

    St. Jude Children's Research Hospital, Memphis, Tennessee

    Locations

    2 in total

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT05468359 on ClinicalTrials.gov

16. 68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)

    The purpose of this study is to look at the effects (good and bad) of a drug called 177Lu-PSMA-617 (also known as the study drug) when given to participants who have prostate specific membrane antigen (PSMA) positive liver cancer.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland, Ohio

    Run by

    Melissa Lumish

    See if you can join NCT06852820 on ClinicalTrials.gov

17. Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

    This phase 1 study is to determine the optimal dose and tolerability of a hypoxia-activating agent, tirapazamine, when it is combined with embolization in liver cancer. Liver cancer patients who are Child-Pugh score A, suitable for embolization with tumor no more than 4 nodules are eligible. Tirapa…

    Stage

    Phase 1

    Ages

    20 to 99

    Site

    Stanford University, Palo Alto, California

    Locations

    2 in total

    Run by

    Teclison Ltd.

    See if you can join NCT02174549 on ClinicalTrials.gov

18. Combination of TATE and PD-1 Inhibitor in Liver Cancer

    This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellula…

    Stage

    Phase 2

    Ages

    18 to 80

    Site

    University of California, Irvine, Orange, California

    Locations

    3 in total

    Run by

    Teclison Ltd.

    See if you can join NCT03259867 on ClinicalTrials.gov

19. Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

    Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver that feeds the tumor, administering chemotherapeutics and the…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania

    Run by

    VA Office of Research and Development

    See if you can join NCT05842174 on ClinicalTrials.gov

20. Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

    The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

    Run by

    Diwakar Davar

    See if you can join NCT07223424 on ClinicalTrials.gov

21. A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

    This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study nea…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Colorado Cancer Center, Aurora, Colorado

    Locations

    5 in total

    Run by

    7 Hills Pharma, LLC

    See if you can join NCT06362369 on ClinicalTrials.gov

22. Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

    The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combinat…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Beverly Hills Cancer Center, Beverly Hills, California

    Locations

    12 in total

    Run by

    Replimune, Inc.

    See if you can join NCT05733598 on ClinicalTrials.gov

23. Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

    This study is a multi-indication, open-label, single-treatment arm, parallel-cohort phase II study of enfortumab vedotin in adult participants with advanced or metastatic colorectal cancer (CRC) or hepatocellular carcinoma (HCC) who have been previously treated with one or more lines of systemic th…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Run by

    H. Lee Moffitt Cancer Center and Research Institute

    See if you can join NCT06553885 on ClinicalTrials.gov

24. SBRT With Atezo/Bev for HCC

    A phase I dose escalation and pharmacodynamic study of repeated dose stereotactic body radiotherapy (SBRT) administered with concurrent atezolizumab and bevacizumab for patients with advanced hepatocellular carcinoma (HCC)

    Stage

    Phase 1

    Ages

    18 to 99

    Site

    Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania

    Run by

    Abramson Cancer Center at Penn Medicine

    See if you can join NCT05488522 on ClinicalTrials.gov

25. Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

    This Phase 1, open-label, non-randomized study will enroll pediatric and young adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety, feasibility, and efficacy of administering T cell products derived fr…

    Stage

    Phase 1

    Ages

    1 to 26

    Site

    Seattle Children's Hospital, Seattle, Washington

    Run by

    Seattle Children's Hospital

    See if you can join NCT07148050 on ClinicalTrials.gov